<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-156654</identifier>
<setSpec>1134-8046</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Desvenlafaxine utility in chronic pain</dc:title>
<dc:description xml:lang="en">Although evidence of desvenlafaxine in neuropathic pain is scarce, it presents some interesting pharmacokinetic properties, as it is not substrate or have activity on P-glycoprotein, and have a metabolism which practically does not depend on cytochrome P450 system, which limits the risk of pharmacokinetic interactions and potential problems associated tolerability when administered with drugs that are CYP2D6 moderate or potent inhibitors or other substrates of this isoenzyme. These characteristics make desvenlafaxine a different antidepressant especially useful in some subgroups of patients with chronic pain (as polypharmacy and patients with liver failure), where comorbid depression is frequent (AU)</dc:description>
<dc:creator>González Curado, A</dc:creator>
<dc:creator>Alcántara Montero, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">Aunque la evidencia de la desvenlafaxina en dolor neuropático es escasa, presenta unas características farmacocinéticas interesantes, como son no ser sustrato ni tener actividad sobre la glicoproteína P, y tener un metabolismo que prácticamente no depende del sistema del citocromo P450, lo que limita el riesgo de interacciones farmacocinéticas y los potenciales problemas de tolerabilidad asociados cuando se administra con fármacos que sean inhibidores moderados o potentes del CYP2D6 o con otros sustratos de esta isoenzima. Estas características hacen de la desvenlafaxina un antidepresivo distinto y especialmente útil en algunos subgrupos de pacientes con dolor crónico (como polimedicados y pacientes con insuficiencia hepática), donde la depresión comórbida es frecuente (AU)</dc:description>
<dc:source>Rev. Soc. Esp. Dolor;23(5): 256-259, sept.-oct. 2016.</dc:source>
<dc:identifier>ibc-156654</dc:identifier>
<dc:title xml:lang="es">Utilidad de la desvenlafaxina en dolor crónico</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d3595^s22021</dc:subject>
<dc:subject>^d54522^s22012</dc:subject>
<dc:subject>^d54522^s22057</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d55909^s22079</dc:subject>
<dc:subject>^d55909^s22073</dc:subject>
<dc:subject>^d55632^s22000</dc:subject>
<dc:subject>^d55868^s22044</dc:subject>
<dc:subject>^d31887^s22012</dc:subject>
<dc:subject>^d33011^s22021</dc:subject>
<dc:subject>^d3952^s22057</dc:subject>
<dc:subject>^d31887^s22057</dc:subject>
<dc:subject>^d55868^s22073</dc:subject>
<dc:subject>^d3952^s22012</dc:subject>
<dc:type>article</dc:type>
<dc:date>201610</dc:date>
</metadata>
</record>
</ibecs-document>
